Bafna Pharmaceuticals Ltd

NSE :BAFNAPH BSE :532989 Sector : Pharmaceuticals

Buy, Sell or Hold BAFNAPH? Ask The Analyst

BSE

prev close

OPEN PRICE

bid price (qty)

offer price (qty)

volume

Today's low / high

52 WK low / high

NSE

prev close

open price

bid price (qty)

offer price (qty)

volume

Today's' low / high

52 WK low / high

26 Apr
86.00
(-0.98%)

25 Apr
86.85
(0.40%)

24 Apr
86.50
(0.58%)

23 Apr
86.00
(0.82%)

22 Apr
85.30
(-1.73%)

19 Apr
86.80
(-0.80%)

18 Apr
87.50
(0.57%)

16 Apr
87.00
(1.16%)

15 Apr
86.00
(-1.15%)

12 Apr
87.00
(-1.69%)

10 Apr
88.50
(-3.23%)

09 Apr
91.45
(1.61%)

08 Apr
90.00
(1.69%)

05 Apr
88.50
(-3.65%)

04 Apr
91.85
(3.84%)

03 Apr
88.45
(4.99%)

02 Apr
84.25
(4.98%)

01 Apr
80.25
(2.43%)

28 Mar
78.35
(0.38%)

27 Mar
78.05
(-0.13%)

26 Mar
78.15
(-1.88%)

Price Chart Historical Data Technical Chart

Technical Analysis

Short Term Investors

Very Bullish

Medium Term Investors

Neutral

Long Term Investors

Very Bullish

Moving Averages

5 DMA

Bullish

87.19

10 DMA

Bullish

87.26

20 DMA

Bullish

85.95

50 DMA

Bullish

86.81

100 DMA

Bearish

92.53

200 DMA

Bullish

Intraday Support and Resistance
(Based on Pivot Points) |

Updated On Apr 26, 2024 04:00 PM For Next Trading Session

Pivots	Classic	Fibonacci	Camarilla	Woodie	DM
R3	93.91	91.93	87.36	-	-
R2	91.93	90.04	86.91	91.69	-
R1	88.96	88.87	86.45	88.48	90.45
P	86.98	86.98	86.98	86.74	87.73
S1	84.01	85.09	85.55	83.53	85.5
S2	82.03	83.92	85.09	81.79	-
S3	79.06	82.03	84.64	-	-

Key Metrics

EPS

4.76

P/E

18.45

P/B

2.52

Dividend Yield

0%

Market Cap

203 Cr.

Face Value

10

Book Value

34.82

ROE

0%

EBITDA Growth

-0.78 Cr.

Debt/Equity

0.7 Shareholding Pattern

	88.3%	Total Promoter Holding

	0%	Mutual Fund Holdings

	0%	FIIs

	11.7%	Non Institution

	0%	Insurance Companies

	0%	Custodians

	0%	Other Parties

Shareholding History

Bafna Pharmaceuticals Ltd Quaterly Results

	Jun 2018	Sep 2018	Jun 2019	Sep 2019
INCOME	12.04	8.8	7.15	12.16
PROFIT	-3.52	-1.28	-2.13	-0.59
EPS	0	-0.8	-0.9	-0.25

Bafna Pharmaceuticals Ltd Quaterly Results

	Jun 2018	Sep 2018	Jun 2019	Sep 2019
INCOME	36.15	42.5	43.82	40.84	29.42
PROFIT	3	5.37	6.35	2.48	-2.94
EPS	1.26	2.27	2.68	1.05	-1.24

Profit & Loss (Figures in Rs. Crores)

Consolidated
Standalone

Bafna Pharmaceuticals Ltd Profit & Loss

	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020
INCOME	137.19	179.76	190.52	131.51	87.95	69.19	74.41	44.22	45.97
PROFIT	1.89	3.86	1.4	-29.84	-14.03	-19.09	-44.58	-19.88	-2.17
EPS	1.04	2.05	0.77	3.33	0	0	0	0	0

Bafna Pharmaceuticals Ltd Profit & Loss

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
INCOME	182.38	131.3	87.87	69.19	74.34	43.21	45.97	69.02	88.61	121.53
PROFIT	1.34	-30.05	-12.18	-18.47	-44.31	-19.73	-1.87	5.83	7.38	11.14
EPS	0.72	3.27	0	0	0	0	-106.54	2.46	2.21	4.79

Balance Sheet (Figures in Rs. Crores)

Consolidated
Standalone

	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013	Mar 2012
SOURCES OF FUNDS :
Share Capital	2.37	23.66	23.66	18.66	18.66	18.66	18.66	18.66	18.38
Reserves Total	-6.61	-4.6	14.27	20.01	39.1	53.12	50.2	45.67	39.57
Equity Share Warrants	0	0	0	4	0	0	0	3.13	5.87
Equity Application Money	55.36	0	0	0	0	0	0	0	0
Total Shareholders Funds	51.12	19.06	37.93	42.67	57.76	71.78	68.86	67.46	63.82
Minority Interest	0.08	-0.21	-0.73	-0.55	0	0.93	0.89	0.85	0.8
Secured Loans	0	44.1	44.37	80.14	80.48	68.65	108.22	100.18	85.44
Unsecured Loans	3.02	2.13	2.17	2.24	0	0	0	0	0
Total Debt	3.02	46.23	46.54	82.38	80.48	68.65	108.22	100.18	85.44
Other Liabilities	0	0.63	12.95	12.79	0.92	0.39	1.29	1.24	0.97
Total Liabilities	54.22	65.71	96.69	137.29	139.16	141.75	179.26	169.73	151.03
APPLICATION OF FUNDS :
Gross Block	74.13	72.91	79.77	79.65	79.67	77.36	90.61	85.98	88.38
Less: Accumulated Depreciation	39.12	35.86	34.88	31.04	27.06	22.8	21.33	12.99	12.14
Net Block	35.01	37.05	44.89	48.61	52.61	54.56	69.28	72.99	76.24
Capital Work in Progress	0.21	0	0	0	0	0	0	0	0
Investments	0	0	0	16.9	16.9	16.9	0	0	0
Inventories	11.41	9.28	10.67	16.74	16.38	16.12	27.4	22.21	23.92
Sundry Debtors	6.03	24.83	24.28	53.78	67.96	88.69	97.51	91.63	83.85
Cash and Bank Balance	8.48	2.71	2.95	2.66	2.71	2.77	2.81	21.07	2.46
Loans and Advances	10.17	11.64	10.83	4.01	35.42	19.51	28.76	43.64	26.39
Total Current Assets	36.1	48.47	48.74	77.18	122.48	127.09	156.48	178.55	136.62
Current Liabilities	17.1	47.58	36.56	38.1	49.74	54.07	50.16	85.03	62.66
Total Current Liabilities & Provisions	17.1	47.58	36.56	38.1	49.74	54.07	50.16	85.03	62.66
Net Current Assets	19	0.89	12.18	39.09	72.74	73.02	106.32	93.53	73.96
Deferred Tax Liability	0	6.18	5.11	2.92	3.82	4	6.41	5.83	5.25
Net Deferred Tax	0	-6.18	-5.11	-2.92	-3.82	-4	-6.41	-5.83	-5.25
Other Assets	0	33.95	44.73	35.61	0.72	1.28	10.07	9.04	6.08
Total Assets	54.22	65.71	96.7	137.29	139.15	141.76	179.26	169.73	151.03
Contingent Liabilities	0.03	0.03	0	0.29	1.64	11.56	18.24	14.07	14.01

	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014
SOURCES OF FUNDS :
Share Capital	23.66	23.66	23.66	2.37	23.66	23.66	18.66	18.66	18.66	18.66
Reserves Total	49.8	38.31	33.11	-6.78	-2.86	16.87	22.32	40.79	52.97	50.12
Equity Share Warrants	0	0	0	0	0	0	4	0	0	0
Equity Application Money	0	0	0	55.36	0	0	0	0	0	0
Total Shareholders Funds	73.46	61.97	56.77	50.95	20.8	40.53	44.98	59.45	71.63	68.78
Secured Loans	21.42	9.04	2.5	0	44.1	44.37	80.14	80.48	63.7	99.34
Unsecured Loans	1.51	2.02	12.79	3.02	2.13	2.17	2.24	0	0	0
Total Debt	22.93	11.06	15.29	3.02	46.23	46.54	82.38	80.48	63.7	99.34
Other Liabilities	1.22	0.85	0.1	0	0.03	0.03	0.03	0.03	0.03	0.93
Total Liabilities	97.61	73.88	72.16	53.97	67.06	87.1	127.39	139.96	135.36	169.05
APPLICATION OF FUNDS :
Gross Block	94.66	87.94	79.57	74.09	72.87	72.54	72.41	72.44	70.14	85.1
Less : Accumulated Depreciation	54.43	49.09	43.6	39.12	35.86	32.6	29.09	25.44	21.51	22.16
Net Block	40.23	38.85	35.97	34.97	37.01	39.94	43.32	47	48.63	62.94
Capital Work in Progress	1.5	0	0.83	0.21	0	0	0	0	0	0
Investments	0	0	0	0	1.43	1.43	18.33	18.33	18.33	1.43
Inventories	22.22	20.28	15.44	11.41	9.28	10.67	16.74	16.35	15.33	26.72
Sundry Debtors	41.15	14.78	9.56	6.03	24.83	24.28	53.7	67.89	83.36	93.1
Cash and Bank Balance	7.81	0.17	1.8	8.48	2.7	2.7	2.66	2.7	2.45	2.47
Loans and Advances	16.13	15.65	22.86	9.95	11.42	10.63	3.75	31.95	16.29	26.7
Total Current Assets	87.31	50.88	49.67	35.88	48.24	48.29	76.85	118.89	117.44	148.99
Current Liabilities	31.36	14.71	14.31	17.1	47.41	35.74	37.26	41.64	46.22	47.57
Provisions	0.63	1.56	0	0	0	0	0	0	0	0
Total Current Liabilities & Provisions	31.99	16.27	14.31	17.1	47.41	35.74	37.26	41.64	46.22	47.57
Net Current Assets	55.33	34.61	35.36	18.78	0.83	12.55	39.58	77.26	71.22	101.42
Deferred Tax Liability	0	0	0	0	6.18	4.68	2.5	3.34	3.68	5.97
Net Deferred Tax	0	0	0	0	-6.18	-4.68	-2.5	-3.34	-3.68	-5.97
Other Assets	0.54	0.42	0	0	33.95	37.86	28.65	0.72	0.86	9.24
Total Assets	97.6	73.88	72.16	53.96	67.05	87.1	127.38	139.96	135.36	169.05
Contingent Liabilities	10.93	6.17	2	5	0.03	0.5	0.29	2.86	11.56	18.24

Cash Flow (Figures in Rs. Crores)

Consolidated
Standalone

Cash from Operating Activity -34.31

Net Profit before Tax and Extr...	-1.88
Depreciation	3.27
Interest (Net)	0.06
Others	-4.75
Total Adjustments (PBT and Ext...	-19.45
Operating Profit before Workin...	-21.34
Trade and 0ther Receivables	18.8
Inventories	-2.13
Trade Payables	-27.02
Loans and Advances	1.47
Total Adjustments (OP before W...	-12.97
Cash Generated from/(used in) ...	-34.31
Cash Flow before Extraordinary...	-34.31
Net Cash from Operating Activi...	-34.31

Cash from Investing Activity 32.77

Purchased of Fixed Assets	-1.43
Interest Received	0.04
Net Cash used in Investing Act...	32.77

Cash from Financing Activity 7.3

Proceeds from Issue of shares ...	55.36
Of the Long Tem Borrowings	-19.97
Of the Short Term Borrowings	-23.24
Interest Paid	-0.1
Net Cash used in Financing Act...	7.3

Cash from Operating Activity 4.95

Net Profit before Tax and Extr...	11.77
Depreciation	5.33
Interest (Net)	1.77
P/L on Sales of Assets	-0.2
Prov. and W/O (Net)	1.08
Total Adjustments (PBT and Ext...	7.88
Operating Profit before Workin...	19.65
Trade and 0ther Receivables	-27.04
Inventories	-1.94
Trade Payables	16.06
Loans and Advances	0.04
Total Adjustments (OP before W...	-14.57
Cash Generated from/(used in) ...	5.08
Direct Taxes Paid	-0.13
Total Adjustments(Cash Generat...	-0.13
Cash Flow before Extraordinary...	4.95
Net Cash from Operating Activi...	4.95

Cash from Investing Activity -7.49

Purchased of Fixed Assets	-6.72
Sale of Fixed Assets	0.2
Interest Received	0.03
Net Cash used in Investing Act...	-7.49

Cash from Financing Activity 10.18

Proceed from 0ther Long Term B...	11.86
Interest Paid	-1.69
Net Cash used in Financing Act...	10.18

Company Details

Registered Office
Address	Bafna Towers New No 68, Old No 299 Thambu Chetty St
City	Chennai
State	Tamil Nadu
Pin Code	600001
Tel. No.	91-44-25267517/25270992/4267755
Fax. No.	91-44-25231264/42677599
Email	cs@bafnapharma.com; info@bafnapharma.com
Internet	http://www.bafnapharma.com

Registrars
Address	Bafna Towers New No 68
City	Chennai
State	Tamil Nadu
Pin Code	600001
Tel. No.	91-44-25267517/25270992/4267755
Fax. No.	91-44-25231264/42677599
Email	cs@bafnapharma.com; info@bafnapharma.com
Internet	http://www.bafnapharma.com

Management
Name	Designation
Babulal Kamlesh Kumar	Non-Exec. & Independent Dir.
Shanmugam Hemalatha	Chairperson / Executive Direct
Akilapriya Chandrashekar Raju	Non-Exec & Non-Independent Dir
Palamadai Krishnan Sundaresan	Non-Exec. & Independent Dir.
Ravichandran Chitra	Non-Exec. & Independent Dir.
Vishnu Vasudeva Kuppa	Company Sec. & Compli. Officer
Upendar Mekala Reddy	Non Executive Director
Krishna Yeachuri	Independent Director
Vinayak Dinesh Dendukuri	Whole-time Director
Upendar Mekala Reddy	Non Executive Director
Krishna Yeachuri	Independent Director

MARKET TODAY

PRODUCTS

SUPPORT

LEGAL & PRIVACY

MAGAZINES

Stocks: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

Data is a real-time snapshot *Data is delayed by at least 15 minutes. StockFact, Market Action Data and Analysis. Data Provider CMOTS Infotech.

Disclaimer : There is no guarantee of profits or no exceptions from losses. The investment advice provided is solely the personal views of the research team. Equitypandit will not accept any liability for loss or damage as a result of reliance on the information contained within this website including data, quotes, charts and buy/sell signals. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. Therefore, Equitypandit doesn't bear any responsibility for any trading losses you might incur as a result of using this data.

Bafna Pharmaceuticals Ltd

Buy, Sell or Hold BAFNAPH? Ask The Analyst

BSE

NSE

Price Chart Historical Data Technical Chart

Technical Analysis

Short Term Investors

Very Bullish

Medium Term Investors

Neutral

Long Term Investors

Very Bullish

Moving Averages

5 DMA

Bullish

10 DMA

Bullish

20 DMA

Bullish

50 DMA

Bullish

100 DMA

Bearish

200 DMA

Bullish

Intraday Support and Resistance (Based on Pivot Points) |

Key Metrics

EPS

4.76

P/E

18.45

P/B

2.52

Dividend Yield

0%

Market Cap

203 Cr.

Face Value

10

Book Value

34.82

ROE

0%

EBITDA Growth

-0.78 Cr.

Debt/Equity

0.7

Shareholding Pattern

Shareholding History

Quarterly Result (Figures in Rs. Crores)

Bafna Pharmaceuticals Ltd Quaterly Results

Bafna Pharmaceuticals Ltd Quaterly Results

Profit & Loss (Figures in Rs. Crores)

Bafna Pharmaceuticals Ltd Profit & Loss

Bafna Pharmaceuticals Ltd Profit & Loss

Balance Sheet (Figures in Rs. Crores)

Cash Flow (Figures in Rs. Crores)

Company Details

Registered Office

Registrars

Management

MARKET TODAY

PRODUCTS

SUPPORT

LEGAL & PRIVACY

MAGAZINES

Intraday Support and Resistance
(Based on Pivot Points) |